As IFNγ signaling has been reported to interact with STAT3, which is considered to promote many tumors including HCC, we next studied whether IFITM1-mediated effects in RT and AT-MSCs combination therapy could affect the expression level of STAT3 (He et al., 2010; Wang et al., 2011). This evidence concerns the gene IFITM1 and hepatocellular carcinoma.